These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 25236765)

  • 21. Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?
    van Ingen J; Aarnoutse RE; Donald PR; Diacon AH; Dawson R; Plemper van Balen G; Gillespie SH; Boeree MJ
    Clin Infect Dis; 2011 May; 52(9):e194-9. PubMed ID: 21467012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks.
    Srivastava S; Deshpande D; Pasipanodya J; Nuermberger E; Swaminathan S; Gumbo T
    Clin Infect Dis; 2016 Nov; 63(suppl 3):S102-S109. PubMed ID: 27742641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In silico evaluation and exploration of antibiotic tuberculosis treatment regimens.
    Pienaar E; Dartois V; Linderman JJ; Kirschner DE
    BMC Syst Biol; 2015 Nov; 9():79. PubMed ID: 26578235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Computational pharmacokinetics/pharmacodynamics of rifampin in a mouse tuberculosis infection model.
    Lyons MA; Lenaerts AJ
    J Pharmacokinet Pharmacodyn; 2015 Aug; 42(4):375-89. PubMed ID: 26026426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis.
    Sirgel FA; Fourie PB; Donald PR; Padayatchi N; Rustomjee R; Levin J; Roscigno G; Norman J; McIlleron H; Mitchison DA
    Am J Respir Crit Care Med; 2005 Jul; 172(1):128-35. PubMed ID: 15805182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population pharmacokinetics of oral levofloxacin in healthy volunteers and dosing optimization for multidrug-resistant tuberculosis therapy.
    Boonpeng A; Jaruratanasirikul S; Wattanavijitkul T; Nawakitrangsan M; Samaeng M
    Biopharm Drug Dispos; 2021 Jul; 42(7):329-337. PubMed ID: 34117648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice.
    Ji B; Truffot-Pernot C; Lacroix C; Raviglione MC; O'Brien RJ; Olliaro P; Roscigno G; Grosset J
    Am Rev Respir Dis; 1993 Dec; 148(6 Pt 1):1541-6. PubMed ID: 8256897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of ofloxacin in drug-resistant tuberculosis.
    Chulavatnatol S; Chindavijak B; Chierakul N; Klomsawat D
    J Med Assoc Thai; 2003 Aug; 86(8):781-8. PubMed ID: 12948278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Attainment of target rifampicin concentrations in cerebrospinal fluid during treatment of tuberculous meningitis.
    Mezochow A; Thakur KT; Zentner I; Subbian S; Kagan L; Vinnard C
    Int J Infect Dis; 2019 Jul; 84():15-21. PubMed ID: 31051278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients.
    Smythe W; Khandelwal A; Merle C; Rustomjee R; Gninafon M; Bocar Lo M; Sow OB; Olliaro PL; Lienhardt C; Horton J; Smith P; McIlleron H; Simonsson US
    Antimicrob Agents Chemother; 2012 Apr; 56(4):2091-8. PubMed ID: 22252827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children.
    Ramachandran G; Hemanth Kumar AK; Bhavani PK; Poorana Gangadevi N; Sekar L; Vijayasekaran D; Banu Rekha VV; Ramesh Kumar S; Ravichandran N; Mathevan G; Swaminathan S
    Int J Tuberc Lung Dis; 2013 Jun; 17(6):800-6. PubMed ID: 23676165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rifampin breakpoint for Acinetobacter baumannii based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation.
    Lepe JA; García-Cabrera E; Gil-Navarro MV; Aznar J
    Rev Esp Quimioter; 2012 Jun; 25(2):134-8. PubMed ID: 22707102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs.
    Goutelle S; Bourguignon L; Maire PH; Van Guilder M; Conte JE; Jelliffe RW
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2974-81. PubMed ID: 19380594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population Pharmacokinetics of Rifampin in Pregnant Women with Tuberculosis and HIV Coinfection in Soweto, South Africa.
    Denti P; Martinson N; Cohn S; Mashabela F; Hoffmann J; Msandiwa R; Castel S; Wiesner L; Chaisson RE; McIlleron H; Dooley KE
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1234-41. PubMed ID: 26643345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages.
    Dhillon J; Mitchison DA
    Am Rev Respir Dis; 1992 Jan; 145(1):212-4. PubMed ID: 1309967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacokinetics of rifampicin in Mexican patients with tuberculosis.
    Milán Segovia RC; Domínguez Ramírez AM; Jung Cook H; Magaña Aquino M; Vigna Pérez M; Brundage RC; Romano Moreno S
    J Clin Pharm Ther; 2013 Feb; 38(1):56-61. PubMed ID: 23167603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mathematical modeling of pulmonary tuberculosis therapy: Insights from a prototype model with rifampin.
    Goutelle S; Bourguignon L; Jelliffe RW; Conte JE; Maire P
    J Theor Biol; 2011 Aug; 282(1):80-92. PubMed ID: 21605569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso.
    Saleri N; Dembélé SM; Villani P; Carvalho AC; Cusato M; Bonkoungou V; Nacanabo R; Kouanda S; Comelli M; Regazzi M; Matteelli A
    J Antimicrob Chemother; 2012 Feb; 67(2):469-72. PubMed ID: 22028201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genitourinary and pulmonary multidrug resistant Mycobacterium tuberculosis infection in an Asian elephant (Elephas maximus).
    Dumonceaux GA; St Leger J; Olsen JH; Burton MS; Ashkin D; Maslow JN
    J Zoo Wildl Med; 2011 Dec; 42(4):709-12. PubMed ID: 22204067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of 2,000 Milligram Ertapenem in Tuberculosis Patients.
    Zuur MA; Ghimire S; Bolhuis MS; Wessels AMA; van Altena R; de Lange WCM; Kosterink JGW; Touw DJ; van der Werf TS; Akkerman OW; Alffenaar JWC
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29439978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.